Opinion

Video

Private Label Biosimilars

Author(s):

Sophia Humphreys, PharmD, MHA, BCBBS,Chad Cannon, PharmD, BCCCP

The expert panel discusses the greater potential for private label biosimilars.

Video content above is prompted by the following questions:

  • Some healthcare companies are investigating the potential for private label biosimilars, including products like adalimumab. What is the value of offering a private label biosimilar to patients? What are some of the challenges that may arise?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
2 experts in this video
2 experts in this video
5 experts in this video
5 experts in this video
2 experts in this video
2 experts in this video
Related Content
Clinician holding piggy bank | Image Credit: Dee Karen - stock.adobe.com
June 2nd 2025

Oncology Biosimilars Offer Potential Relief From Financial Burden of Cancer Care

Brooke McCormick
Oncology biosimilars significantly reduce financial toxicity in cancer care, as highlighted in 2 abstracts presented at the 2025 American Society of Clinical Oncology Annual Meeting.
managed care cast banner
August 17th 2022

How Health Care Institutions Can Leverage Biosimilars to Generate Savings

Skylar Jeremias
On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.
FDA Approved. | Image Credit: Nirusmee - stock.adobe.com
February 20th 2025

First Insulin Aspart Biosimilar Receives FDA Approval

Cameron Santoro
Merilog (insulin-aspart-szjj) is the first rapid-acting insulin biosimilar to Novolog (insulin aspart) that is designated to improve glycemic control in adults and adolescents with type 2 diabetes.
Managed Care Cast
June 14th 2022

Biosimilar Whisky? This Expert Says It’s Doable, No Aging Required

On this episode of Managed Care Cast, we’re highlighting a hobby from a biosimilar expert who says he can make whisky more accessible and affordable through—you guessed it—his own biosimilar whisky.
Insulin. | Image Credit: Sherry Young- stock.adobe.com
February 12th 2025

Biosimilar Insulin Linked to Lower Prices in Europe

Cameron Santoro
The introduction of insulin glargine biosimilars is associated with significant price reductions across European markets.
FDA approved. | Image Credit: Olivier Le Moal - stock.adobe.com
January 31st 2025

FDA Approves Celltrion’s Tocilizumab-anoh, Biosimilar to Actemra

Cameron Santoro
Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo